Skip to main content

Gilead to buy cancer drugmaker Immunomedics in $21 billion deal

Gilead to buy cancer drugmaker Immunomedics in $21 billion deal  image

Gilead to buy cancer drugmaker Immunomedics in $21 billion deal - CNBC

The deal will provide Gilead access to Immunomedics' cancer treatment drug called Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer.
Read More

In Similar Category

From CNBC